Clinical characteristics of 20 rare diseases in children based on specific disease data

  • Shuai ZHAO ,
  • Ang MA ,
  • Shuying LUO ,
  • Songchen XIA ,
  • Chanjuan HAO ,
  • Wei LI ,
  • Haiyan WEI ,
  • Yaodong ZHANG
Expand
  • 1. Henan children's Hospital Children’s Hospital Affiliated to Zhengzhou University Henan Key Laboratory of Children’s Genetics and Metabolic Diseases, Zhengzhou 450018, Henan, China
    2. National Children's Medical Center Institute of Pediatrics, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
    3. Yidu Cloud (Beijing) Technology Co., Ltd., Beijing 100010, China

Received date: 2023-08-15

  Online published: 2024-02-02

Abstract

Objective The purpose of this study is to explore and evaluate the clinical characteristics of children with different rare diseases by using the database of children's rare diseases in our hospital, so as to provide a basis for promoting the prevention, diagnosis and treatment of children with rare diseases. Methods The data of children in our rare disease database (Phase I) were analysed from 16th May 2011 to 29th January 2023 by child admission. The International Classification of Diseases (ICD-10) was used to classify and count the number of cases mined, gender, geography, age, genetic tests, repeat visits and hospitalisations. Results A total of 3491 children were included in the database, covering 20 rare diseases, representing 9.7% (20/207) of the rare disease catalogue. The ratio of male to female patients was 1.30:1 (1975 males/1516 females). Methylmalonic acidemia (1024 cases, 29.33%), congenital adrenocortical hyperplasia (944 cases, 27.04%) and phenylketonuria (191 cases, 5.47%) were the top three rare diseases. Genetic testing data were included in 220 cases, accounting for 6.30% of the total number of diseases. Hospitalised cases covered 16 provinces, with Henan province accounting for 96.60% of cases (1988/2058). Rare diseases in infancy accounted for 42.36% (1479/3491) of the total number of cases. Multiple osteofibrous dysplasia with precocious puberty syndrome was the highest percentage of repeat hospitalisation for rare diseases at 24.24% (8/33), while children with Kalman syndrome had the highest rate of repeat outpatient visits at 51.85% (14/27). Conclusion Based on the database of special diseases, we analyzed the clinical characteristics of 20 rare diseases in children, which provided a reference for promoting the prevention, control, detection and research of rare diseases in children in our province.

Cite this article

Shuai ZHAO , Ang MA , Shuying LUO , Songchen XIA , Chanjuan HAO , Wei LI , Haiyan WEI , Yaodong ZHANG . Clinical characteristics of 20 rare diseases in children based on specific disease data[J]. Journal of Clinical Pediatrics, 2024 , 42(2) : 110 -115 . DOI: 10.12372/jcp.2024.23e0781

References

[1] Rodríguez-Blanque R, Sánchez-García JC, Cortés-Martín J. Pregnancy, childbirth, puerperium, breastfeeding, and sexuality in the world of rare diseases[J]. Healthcare (Basel), 2023, 11(9): 5-8.
[2] 徐陆欣怡, 王妮, 尹适成, 等. 我国罕见病药品的可及性及采购使用现状研究[J]. 中国卫生政策研究, 2022, 15(2): 60-64.
[3] 彭镜. 儿童神经遗传罕见病进入疾病修正治疗时代[J]. 中华儿科杂志, 2022, 60(11): 1097-1099.
[4] Brock DC, Demarest S, Benke TA. Clinical trial design for disease-modifying therapies for genetic epilepsies[J]. Neurotherapeutics, 2021, 18(3): 1445-1457.
[5] 张皖晋, 卓阳, 孙搏. 欧美罕见病药物研发的监管机制分析及启示[J]. 中国新药与临床杂志, 2023, 42(2): 85-90.
[6] 温馨, 王杉杉, 蔡剑, 等. 浙江省2007-2017年罕见病住院病例特征分析[J]. 中华流行病学杂志, 2020, 41(3): 400-405.
[7] 潘锋, 赵海. 探索建立多层次罕见病医疗保障新体系[J]. 中国医药科学, 2023, 13(7): 4-6.
[8] 吴斯旻. 罕见病目录扩容业界人士喜忧参半[N]. 第一财经日报, 2023-09-28( A06).
[9] 王丽雯, 倪敏, 贾晨路, 等. 应用串联质谱技术进行河南省新生儿甲基丙二酸血症的筛查结果分析[J]. 中国优生与遗传杂志, 2019, 27(7): 846-848.
[10] 陆相朋, 郑宏, 梁瑞星, 等. 甲基丙二酸血症86例患儿的神经发育特征[J]. 中华实用儿科临床杂志, 2020(3): 221-226.
[11] 于玥, 凌诗颖, 帅瑞雪, 等. 720例甲基丙二酸血症MMACHC基因c.609G>A变异患者临床特征及随访分析[J]. 浙江大学学报(医学版), 2021, 50(4): 436-443.
[12] 张米妮, 余婷婷, 符皓, 等. McCune-Albright综合征患儿临床特征分析[J]. 中华实用儿科临床杂志, 2022, 37(24): 1883-1887.
[13] 池欢. 2012-2018年重庆医科大学附属儿童医院1975例儿童罕见病住院患者疾病特征分析[D]. 重庆医科大学, 2019.
[14] 张慧, 刘小红, 杨永华. 儿童罕见病药物临床试验伦理保护的思考[J]. 中国医学伦理学, 2022, 35(5): 494-498.
[15] Kumar KS, Naleer MH, Visweswaran V, et al. Melanotic neuroectodermal tumor of infancy: a rare case report[J]. Asian J Neurosurg, 2022, 17(1): 131-133.
[16] 唐怡珺, 张倩文, 王依柔, 等. Kallmann综合征临床特点及基因型分析[J]. 临床儿科杂志, 2023, 41(7): 537-542.
[17] Hart ES, Kelly MH, Brillante B, et al. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome[J]. J Bone Miner Res, 2007, 22(9):1468-1474.
[18] 王晓乐, 林雪芹, 贺海兰, 等. 腺相关病毒介导的基因治疗在儿童神经遗传罕见病中应用的现状与展望[J]. 中南大学学报(医学版), 2023: 1-10.
[19] Glenn DA, Hogan SL. Big data and glomerular disease: uncovering common outcomes of rare disease[J]. J Am Soc Nephrol, 2021, 32(9): 2106-2108.
[20] Bai JP, Wang J, Zhang Y, et al. Quantitative systems pharmacology for rare disease drug development[J]. J Pharm SCI-US, 2023, 112 (9): 2313-2320.
[21] Kim SY, Shin JS, Jang MS, et al. Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up[J]. Arch Dis Child, 2022, 108(4): 307-312.
[22] 郭健, 吕浩涵, 李杰, 等. 中国国家罕见病注册系统架构和数据质量控制及管理流程[J]. 中国数字医学, 2021, 16(1): 17-22.
Outlines

/